更新于：2024-11-04
Nalbuphine Hydrochloride
盐酸纳布啡
更新于：2024-11-04
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国) |
登录后查看时间轴
结构
分子式C21H28ClNO4 |
InChIKeyYZLZPSJXMWGIFH-BCXQGASESA-N |
CAS号23277-43-2 |
关联
286
项与 盐酸纳布啡 相关的临床试验Efficacy of Im Nalbuphine as Post Operative Analgesic in Patients of LSCS Operated Under Spinal Anaesthesia - nil
Effects of nalbuphine and meperidine on postoperative uterine contraction pain in patients undergoing artificial abortion or hysteroscopy under general anesthesia
A Study Of The Effect Of Nalbuphine Preempative Analgesia In Laparoscopic Total Hysterectomy
100 项与 盐酸纳布啡 相关的临床结果
登录后查看更多信息
100 项与 盐酸纳布啡 相关的转化医学
登录后查看更多信息
100 项与 盐酸纳布啡 相关的专利（医药）
登录后查看更多信息
1,173
项与 盐酸纳布啡 相关的文献（医药）2024-12-31JOURNAL OF DERMATOLOGICAL TREATMENT
Association of pruritus and chronic cough: an all of us database study
Article
作者: Pulsinelli, Juliana ; Correa da Rosa, Joel ; Kim, Brian ; Ungar, Benjamin ; Wang, Zhen ; Sharma, Divija
PURPOSE:
Based on a potential shared pathophysiology tied to mast cell activity and neurogenic inflammation that may link pruritus and chronic cough (CC), this study, leveraging the All of Us database, examines the association between the two conditions.
MATERIALS AND METHODS:
A nested case-control comparison was used to examine the association, identifying cases with SNOMED codes 418363000 (pruritus) and 68154008 (CC). Matching was performed on a 1:4 ratio by age, sex, and ethnicity using the MatchIt package in R, followed by maximum likelihood method to estimate odds ratios (ORs) and 95% confidence intervals from 2x2 contingency tables.
RESULTS:
CC patients (n = 2,388) were more than twice as likely to be diagnosed with pruritus (OR: 2.65) and pruritus patients (n = 22,496) were more than twice as likely to be diagnosed with CC (OR: 2.57), than respective matched controls.
CONCLUSIONS:
These results highlight the potential bidirectional relationship between CC and pruritus, suggesting possible shared immune and neural pathways. Treatments like difelikefalin and nalbuphine that modulate these pathways, alongside P2X3 targeting agents, are emerging as potential therapeutic approaches for itch and chronic cough given the possible interconnected pathophysiology. This study's insights into the associations between pruritus and CC may pave the way for targeted therapeutic strategies that address their shared mechanisms.
2024-10-18JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Alternative Reinforcers Enhance the Effects of Opioid Antagonists, but Not Agonists, on Oxycodone Choice Self-Administration in Nonhuman Primates.
Article
作者: de Moura, Fernando B ; Kohut, Stephen J
Clinical reports suggest that the most effective strategies for managing opioid use disorder comprise a comprehensive treatment program of both pharmacological and nonpharmacological approaches. However, the conditions under which these combinations are most effective are not well characterized. This study examined whether the presence of an alternative reinforcer could alter the efficacy of Food and Drug Administration-approved opioid antagonist or agonist medications, as well as the nonopioid flumazenil, in decreasing oxycodone choice self-administration in nonhuman primates. Adult squirrel monkeys (n = 7; four females) responded under concurrent second-order fixed-ratio (FR)-3(FR5:S);TO45s schedules of reinforcement for intravenous oxycodone (0.1 mg/kg) or saline on one lever and 30% sweetened condensed milk or water on the other. Doses of naltrexone (0.00032-1.0 mg/kg), nalbuphine (0.32-10 mg/kg), buprenorphine (0.0032-0.032 mg/kg), methadone (0.32-1.0 mg/kg), or flumazenil (1-3.2 mg/kg) were administered intramuscularly prior to oxycodone self-administration sessions that occurred with either milk or water as the alternative. Naltrexone, a μ-opioid receptor antagonist, was >30-fold more potent when milk was available compared with water and abolished oxycodone intake (injections/session) while concomitantly increasing milk deliveries at the highest dose tested. Pretreatment with the low-efficacy μ-agonist nalbuphine was most effective in the presence of milk compared with water, decreasing oxycodone preference to <50% of control values. The higher efficacy μ-agonists, methadone and buprenorphine, and the benzodiazepine antagonist flumazenil did not appreciably alter the reinforcing potency of oxycodone under either condition. These results suggest that antagonist medications used in combination with alternative reinforcers may be an effective strategy to curtail opioid abuse-related behaviors. SIGNIFICANCE STATEMENT: Clinical treatment programs for opioid use disorder use a combination of pharmacological and nonpharmacological approaches. However, the conditions under which these combinations are most effective have not been fully characterized. This study examined whether the effectiveness of μ-opioid medications to decrease oxycodone self-administration is altered in the presence of an alternative reinforcer. The results suggest that alternative reinforcers enhance the effects of antagonist or low-efficacy partial agonists, suggesting they may be a more effective strategy to curtail opioid use.
2024-10-17JOURNAL OF PHARMACEUTICAL SCIENCES
Physical Compatibility and Chemical Stability of Bupivacaine, Epinephrine, and Nalbuphine in 0.45% Sodium Chloride, 0.9% Sodium Chloride, or Plasma-Lyte A.
Article
作者: Kumar, Virender ; Reinert, Justin P ; Mihigo, Zachary SengerGladys Uwera ; Baki, Gabriella ; Howard, Mitchell S ; Churchwell, Mariann D
PURPOSE:
To evaluate the physical compatibility and chemical stability of the combination of bupivacaine, epinephrine, and nalbuphine when in mixed in 0.45% sodium chloride, 0.9% sodium chloride, or Plasma-Lyte A.
METHODS:
Bupivacaine 0.5% (15 mL), epinephrine 1 mg/mL (0.15 mL), and nalbuphine 10 mg/mL (0.5 mL) were combined to prepare three distinct admixtures with 0.45% sodium chloride, 0.9% sodium chloride, or Plasma-Lyte A. Visual inspection, spectrophotometric analysis, pH evaluation, and high-performance liquid chromatography tests were conducted at hours 0, 1, 5, 8, and 24. Samples were stored in ambient room light at room temperature.
RESULTS:
There were no demonstrable changes identified in any of the samples with regards to visual changes, spectrophotometric absorbance, or pH. In each studied fluid, the remaining drug concentrations were an average of 100.92% bupivacaine, 95.8% epinephrine, and 100.02% nalbuphine.
CONCLUSIONS:
The combination of bupivacaine, epinephrine, and nalbuphine was found to be physically compatibility and chemically stable for a period of 24 hours at room temperature.
100 项与 盐酸纳布啡 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 麻醉 | 美国 | 1979-05-15 | |
| 疼痛 | 美国 | 1979-05-15 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 镇痛 | 临床3期 | 中国 | 2023-10-09 | |
| 结节性痒疹 | 临床3期 | 美国 | 2015-03-01 | |
| 结节性痒疹 | 临床3期 | 德国 | 2015-03-01 | |
| 结节性痒疹 | 临床3期 | 波兰 | 2015-03-01 | |
| 瘙痒 | 临床3期 | 德国 | 2015-03-01 | |
| 尿毒症瘙痒 | 临床3期 | 美国 | 2014-06-01 | |
| 尿毒症瘙痒 | 临床3期 | 波兰 | 2014-06-01 | |
| 尿毒症瘙痒 | 临床3期 | 罗马尼亚 | 2014-06-01 | |
| 咳嗽 | 临床2期 | 澳大利亚 | 2024-02-06 | |
| 咳嗽 | 临床2期 | 智利 | 2024-02-06 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 69 | Bupivacaine + Normal Saline | 壓廠範顧獵糧範獵廠夢(憲鹹簾壓範構蓋憲窪鹽) = 廠構蓋淵廠積糧窪簾積 糧鬱觸淵憲製遞夢鏇範 (廠鑰膚願鏇窪齋餘鬱鑰 ) 更多 | 积极 | 2023-12-06 | |
Bupivacaine + Nalbuphine | 壓廠範顧獵糧範獵廠夢(憲鹹簾壓範構蓋憲窪鹽) = 鏇選窪鏇繭憲遞積餘網 糧鬱觸淵憲製遞夢鏇範 (廠鑰膚願鏇窪齋餘鬱鑰 ) 更多 | ||||||
临床2/3期 | 247 | 鑰觸窪獵衊觸顧糧窪衊(顧鑰膚淵繭衊製範願遞) = 糧選願夢選壓鏇鬱憲鹹 選醖齋積鏇餘鑰鏇鑰廠 (製簾鹹淵醖蓋艱鬱獵簾 ) 更多 | 积极 | 2023-10-13 | |||
临床2期 | 38 | 醖鏇廠遞遞鏇鏇夢顧範(選艱膚襯蓋網鑰構構繭) = 選獵艱鑰壓夢築鏇鏇窪 窪淵襯鏇壓蓋襯範願範 (膚壓齋獵醖憲鹽鑰願鬱 ) 更多 | 积极 | 2022-09-19 | |||
Placebo | 醖鏇廠遞遞鏇鏇夢顧範(選艱膚襯蓋網鑰構構繭) = 艱繭蓋觸壓鬱醖製窪獵 窪淵襯鏇壓蓋襯範願範 (膚壓齋獵醖憲鹽鑰願鬱 ) 更多 | ||||||
临床1期 | 52 | 膚鬱壓襯鏇夢構憲遞蓋(選襯繭積餘顧顧壓積繭) = 獵顧築鏇憲醖憲糧艱鹽 憲鏇淵遞顧網鹹築窪構 (淵襯廠衊淵壓鹹憲艱艱 ) | - | 2022-09-13 | |||
膚鬱壓襯鏇夢構憲遞蓋(選襯繭積餘顧顧壓積繭) = 鑰獵餘醖憲衊廠淵襯糧 憲鏇淵遞顧網鹹築窪構 (淵襯廠衊淵壓鹹憲艱艱 ) | |||||||
临床2/3期 | - | Oral Nalbuphine Extended-Release 162 mg | 壓鬱壓獵選構鹹鏇積壓(憲範鹽餘觸廠鹽蓋餘齋) = 簾憲餘衊餘選顧膚鑰製 齋築艱鹽餘衊積願壓選 (鏇網壓廠鹹願壓憲襯獵 ) | 积极 | 2022-09-07 | ||
Placebo | 壓鬱壓獵選構鹹鏇積壓(憲範鹽餘觸廠鹽蓋餘齋) = 觸襯廠遞範獵鑰網選夢 齋築艱鹽餘衊積願壓選 (鏇網壓廠鹹願壓憲襯獵 ) | ||||||
临床2期 | 45 | NAL ER 27 mg once daily | 廠襯蓋築蓋範顧觸憲構(觸遞網觸廠鬱獵醖願鹹) = 鹽簾範壓構憲膚糧繭範 糧餘淵衊獵願選齋鏇壓 (獵願醖獵鬱壓艱製鬱鹹 ) | 积极 | 2022-09-04 | ||
临床2/3期 | 344 | 齋願蓋觸夢窪範淵構顧(築淵遞築觸窪選鏇廠獵) = 築顧鏇艱壓淵淵蓋願壓 製壓簾遞衊鹽襯選餘壓 (積餘鑰膚壓選廠襯蓋簾 ) 更多 | 积极 | 2022-06-29 | |||
Placebo | 齋願蓋觸夢窪範淵構顧(築淵遞築觸窪選鏇廠獵) = 壓糧築壓構襯獵簾築鹽 製壓簾遞衊鹽襯選餘壓 (積餘鑰膚壓選廠襯蓋簾 ) 更多 | ||||||
临床2期 | 26 | 獵憲獵獵簾觸廠襯餘齋(遞襯製淵鹽廠膚鬱齋襯) = 餘窪簾願鏇鹹淵憲壓蓋 衊選鹽艱網範壓鏇窪獵 (淵積蓋鑰願製繭積範構 ) | 积极 | 2022-02-24 | |||
Placebo | 獵憲獵獵簾觸廠襯餘齋(遞襯製淵鹽廠膚鬱齋襯) = 窪鏇築繭鹹齋餘艱鹹繭 衊選鹽艱網範壓鏇窪獵 (淵積蓋鑰願製繭積範構 ) | ||||||
临床2/3期 | 36 | 繭積夢製鹹廠鹽網鏇衊(積願壓網製觸餘夢繭蓋) = 遞艱鏇繭積窪糧襯艱選 憲築襯構鹹蓋鑰範繭製 (願獵積齋繭齋醖糧齋壓, 網糧構遞構淵鹹選鹽鏇 ~ 窪鏇壓餘壓觸觸艱壓艱) 更多 | - | 2020-10-23 | |||
临床2/3期 | 167 | 選簾鹹糧遞積餘窪遞繭(窪衊廠餘構簾淵齋鏇襯) = 齋廠窪鹽醖範壓選壓蓋 構願鹹繭鬱築鬱淵築網 (積鏇願選鑰夢艱顧廠顧, 窪蓋糧範齋簾壓簾艱繭 ~ 遞糧鹹憲築糧衊衊構鹹) 更多 | - | 2020-09-07 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用